Reviewing Acumen Pharmaceuticals (NASDAQ:ABOS) & SQZ Biotechnologies (NYSE:SQZ)

Acumen Pharmaceuticals (NASDAQ:ABOSGet Rating) and SQZ Biotechnologies (NYSE:SQZGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

64.4% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 66.6% of SQZ Biotechnologies shares are held by institutional investors. 4.7% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Acumen Pharmaceuticals and SQZ Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acumen Pharmaceuticals N/A -17.45% -13.08%
SQZ Biotechnologies -303.43% -57.79% -32.71%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Acumen Pharmaceuticals and SQZ Biotechnologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acumen Pharmaceuticals 0 0 4 0 3.00
SQZ Biotechnologies 0 0 2 0 3.00

Acumen Pharmaceuticals currently has a consensus price target of $21.25, indicating a potential upside of 566.14%. SQZ Biotechnologies has a consensus price target of $28.50, indicating a potential upside of 831.37%. Given SQZ Biotechnologies’ higher probable upside, analysts plainly believe SQZ Biotechnologies is more favorable than Acumen Pharmaceuticals.

Valuation and Earnings

This table compares Acumen Pharmaceuticals and SQZ Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acumen Pharmaceuticals $1.44 million 89.72 -$100.61 million N/A N/A
SQZ Biotechnologies $27.10 million 3.18 -$68.74 million ($2.64) -1.16

SQZ Biotechnologies has higher revenue and earnings than Acumen Pharmaceuticals.

Acumen Pharmaceuticals Company Profile (Get Rating)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

SQZ Biotechnologies Company Profile (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Want More Great Investing Ideas?

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.